glp 1 tirzepatide Compounded GLP-1 - Semaglutide & Lose up to 20% of your body weight with this simple Compound Tirzepatide

The breakdown of GIP and GLP-1 by DPP-4 occurs approximately 4 min after these hormones enter the circulation

PMCID: PMC8294388

In a 2023 systematic review of the effectiveness of several obesity medications, semaglutide achieved the greatest mean weight loss, a finding that was echoed in a 2022 JAMA paper comparing semaglutide with liraglutide (figure 4) .* There is evidence to suggest that tirzepatide, currently approved for use as a diabetes medication but not yet as a weight loss drug, is superior still to semaglutide

Gastrointestinal side effects may include constipation, biliary disease, bowel obstruction or gastroparesis, among others

suppl 3 S434-S442

When tirzepatide binds to GIP receptors, it triggers insulin release only when blood glucose is elevated, reducing hypoglycemia risk